Ostalo

https://doi.org/10.20471/acc.2018.57.03.22

Uncommon Side Effects of Sunitinib Therapy in a Patient with Metastatic Renal Cell Cancer: Case Report

Robert Šeparović orcid.org/0000-0002-4002-2699 ; Sestre milosrdnice University Hospital Centre, University Hospital for Tumors, Department of Internist Oncology, Zagreb, Croatia
Mirjana Pavlović orcid.org/0000-0002-9633-064X ; Sestre milosrdnice University Hospital Centre, University Hospital for Tumors, Department of Internist Oncology, Zagreb, Croatia
Tajana Silovski orcid.org/0000-0002-4699-5432 ; Sestre milosrdnice University Hospital Centre, University Hospital for Tumors, Department of Internist Oncology, Zagreb, Croatia
Hrvoje Silovski ; Zagreb University Hospital Centre, Department of Gastrointestinal Surgery, Zagreb, Croatia
Ana Tečić Vuger orcid.org/0000-0003-2203-161X ; Sestre milosrdnice University Hospital Centre, University Hospital for Tumors, Department of Internist Oncology, Zagreb, Croatia

Sažetak

Sunitinib is an orally administered multikinase inhibitor. This therapy can provoke uncommon side effects such as pancytopenia, tumor lysis syndrome, cardiac disorders, thromboembolic incidents, intestinal perforation, pancreatitis, acute renal failure, etc. We report a case of a 63-year-old female admitted to the hospital due to abdominal pain, nausea, vomiting and elevated blood pressure. One month earlier, sunitinib therapy for metastatic renal cell carcinoma was initiated. During the first cycle of therapy, after three weeks of sunitinib 50 mg daily, symptoms started and she stopped taking the drug. At admission, laboratory tests revealed elevated serum and urine amylase, C-reactive protein, urea and creatinine, and lowered platelet and leukocyte counts and hemoglobin value. Urine test showed proteinuria, erythrocyturia, leukocyturia and granulated cylinder. The patient was diagnosed with acute pancreatitis grade III, acute renal failure grade II, pancytopenia and urinary infection, and was hospitalized for five days. She was treated symptomatically and with antibiotic therapy because of persistently elevated C-reactive protein and pathologic urinary sediment, which led to subjective and clinical improvement. Acute pancreatitis, renal insufficiency and pancytopenia are rarely described side effects of sunitinib therapy, and clear connection between these conditions and drug activity is not yet determined. Medical specialists who prescribe and treat patients with sunitinib should be aware of the possible occurrence of these conditions and perform regular checkups of sunitinib treated patients.

Ključne riječi

Sunitinib; Carcinoma, renal cell; Drug-related side effects and adverse reactions; Pancreatitis; Acute kidney injury; Pancytopenia

Hrčak ID:

216176

URI

https://hrcak.srce.hr/216176

Datum izdavanja:

1.9.2018.

Podaci na drugim jezicima: hrvatski

Posjeta: 3.414 *